清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Repotrectinib: First Approval

医学 trk受体 ROS1型 酪氨酸激酶 癌症研究 癌症 肿瘤科 原肌球蛋白受体激酶A 靶向治疗 受体酪氨酸激酶 肺癌 原肌球蛋白受体激酶B 内科学 神经营养素 腺癌 受体 神经营养因子
作者
Sohita Dhillon
出处
期刊:Drugs [Adis, Springer Healthcare]
卷期号:84 (2): 239-246 被引量:27
标识
DOI:10.1007/s40265-023-01990-6
摘要

Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content. Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable. Additional information about this Adis Drug Review can be found here. Abstract Repotrectinib (AUGTYRO™) is a next-generation, oral, small-molecule kinase inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC. It is being developed by Turning Point Therapeutics, a wholly owned subsidiary of Bristol-Myers Squibb (BMS), for the treatment of locally advanced or metastatic solid tumours, including non-small cell lung cancer (NSCLC). Repotrectinib is a next-generation tyrosine kinase inhibitor rationally designed to inhibit ROS1 and TRK fusion, including in the presence of resistance mutations such as solvent-front mutations. In November 2023, repotrectinib received its first approval in the USA for the treatment of adults with locally advanced or metastatic ROS1-positive NSCLC. Repotrectinib is under regulatory review in China and the EU for NSCLC. Clinical studies of repotrectinib are ongoing in several countries in patients with NSCLC and other solid tumours (including primary central nervous system cancer) across both adult and paediatric patient populations. In addition, preclinical investigation of repotrectinib in multiple myeloma is underway in the USA. This article summarizes the milestones in the development of repotrectinib leading to this first approval for the treatment of locally advanced or metastatic ROS1-positive NSCLC. © Springer Nature Switzerland AG 2023
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
清爽的天川完成签到,获得积分10
1秒前
灵巧怀曼完成签到,获得积分10
10秒前
yan完成签到,获得积分10
18秒前
美满尔蓝完成签到,获得积分10
19秒前
dianeil发布了新的文献求助10
22秒前
舒适的妍完成签到,获得积分10
22秒前
丰富广缘完成签到,获得积分10
25秒前
求求了给篇文献完成签到,获得积分10
29秒前
温暖友易完成签到,获得积分10
29秒前
2s完成签到,获得积分10
31秒前
31秒前
腼腆的冰安完成签到,获得积分10
33秒前
顺利毛豆完成签到,获得积分10
34秒前
陈微完成签到,获得积分10
34秒前
2s发布了新的文献求助10
36秒前
能毕业就行完成签到,获得积分10
37秒前
单薄飞双完成签到,获得积分10
39秒前
苏苏完成签到,获得积分10
39秒前
张永和完成签到,获得积分10
41秒前
威武的成协完成签到,获得积分10
42秒前
无情捕完成签到,获得积分10
43秒前
科研绿老头完成签到,获得积分10
48秒前
小蘑菇的应助被科研通管家采纳,获得10
50秒前
null的应助被科研通管家采纳,获得10
50秒前
深情安青的应助被科研通管家采纳,获得10
50秒前
null的应助被科研通管家采纳,获得10
50秒前
周新哲完成签到,获得积分10
50秒前
Muth完成签到,获得积分10
52秒前
dingyushu完成签到,获得积分10
52秒前
ZF完成签到,获得积分10
52秒前
WULAVIVA完成签到,获得积分10
54秒前
2dingyushu完成签到,获得积分10
57秒前
仇敌克星完成签到,获得积分10
58秒前
baa完成签到,获得积分10
58秒前
du完成签到,获得积分10
59秒前
zheng完成签到,获得积分10
1分钟前
Beto发布了新的文献求助10
1分钟前
慢波完成签到,获得积分10
1分钟前
9dingyushu完成签到,获得积分10
1分钟前
秋风之墩完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185411
求助须知:如何正确求助?哪些是违规求助? 9574140
关于积分的说明 21834410
捐赠科研通 7782895
什么是DOI,文献DOI怎么找? 3434567
关于科研通互助平台的介绍 2558844
邀请新用户注册赠送积分活动 2481280